# Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

> **NCT04489537** · PHASE3 · TERMINATED · sponsor: **Catalyst Biosciences** · enrollment: 18 (actual)

## Conditions studied

- Hemophilia A With Inhibitor
- Hemophilia B With Inhibitor

## Interventions

- **BIOLOGICAL:** MarzAA

## Key facts

- **NCT ID:** NCT04489537
- **Lead sponsor:** Catalyst Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-04
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-12-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Sponsor decision (not a safety decision)
- **Last updated:** 2021-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489537, "Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04489537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*